GlobeNewswire Inc.··Chiesi Global Rare Diseases / Protalix BiotherapeuticsElfabrio Wins EU Approval for Less-Frequent Dosing, Triggering $25M Payment
European Commission approves every-4-weeks dosing regimen for Elfabrio, reducing patient treatment burden and triggering $25 million milestone payment to Protalix from Chiesi.
PLXrare diseaseEuropean Commission approval